Geetha Beauchamp
Overview
Explore the profile of Geetha Beauchamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Okafor C, Hucks-Ortiz C, Hightow-Weidman L, Magnus M, Emel L, Beauchamp G, et al.
J Acquir Immune Defic Syndr
. 2020 May;
85(1):23-29.
PMID: 32452970
Background: Pre-exposure prophylaxis (PrEP) is efficacious for HIV prevention. Black men who have sex with men (MSM) accounted for the largest proportion of new HIV diagnoses in the United States...
12.
El-Sadr W, Beauchamp G, Hall H, Torian L, Zingman B, Lum G, et al.
J Acquir Immune Defic Syndr
. 2019 Jun;
81(3):300-303.
PMID: 31194704
Background: Results from the HPTN 065 study showed that financial incentives (FI) were associated with significantly higher viral load suppression and higher levels of engagement in care among patients at...
13.
Wheeler D, Fields S, Beauchamp G, Chen Y, Emel L, Hightow-Weidman L, et al.
J Int AIDS Soc
. 2019 Feb;
22(2):e25223.
PMID: 30768776
Introduction: Randomized clinical trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV acquisition among men who have sex with men (MSM). However, limited research has examined...
14.
Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson J, et al.
Value Health
. 2019 Feb;
22(2):194-202.
PMID: 30711064
Objective: To evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care. Study Design: Mathematical model of 2-year intervention offering financial incentives...
15.
Hightow-Weidman L, Magnus M, Beauchamp G, Hurt C, Shoptaw S, Emel L, et al.
Clin Infect Dis
. 2019 Jan;
69(9):1597-1604.
PMID: 30615169
Background: The HIV Prevention Trials Network (HPTN) Study 073 (HPTN 073) assessed the feasibility, acceptability, and safety of preexposure prophylaxis (PrEP) for black men who have sex with men (BMSM)....
16.
Wheeler D, Lucas J, Wilton L, Nelson L, Hucks-Ortiz C, Watson C, et al.
J Int AIDS Soc
. 2018 Oct;
21 Suppl 7:e25180.
PMID: 30334600
No abstract available.
17.
Branson B, Chavez P, Hanscom B, Greene E, McKinstry L, Buchacz K, et al.
Clin Infect Dis
. 2017 Nov;
66(10):1581-1587.
PMID: 29186421
Background: Human immunodeficiency virus (HIV) testing is critical for both HIV treatment and prevention. Expanding testing in hospital settings can identify undiagnosed HIV infections. Methods: To evaluate the feasibility of...
18.
El-Sadr W, Donnell D, Beauchamp G, Hall H, Torian L, Zingman B, et al.
JAMA Intern Med
. 2017 Jun;
177(8):1083-1092.
PMID: 28628702
Importance: Achieving linkage to care and viral suppression in human immunodeficiency virus (HIV)-positive patients improves their well-being and prevents new infections. Current gaps in the HIV care continuum substantially limit...
19.
Zhang Y, Clarke W, Marzinke M, Piwowar-Manning E, Beauchamp G, Breaud A, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(7).
PMID: 28438932
Daily oral tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) is a safe and effective intervention for HIV preexposure prophylaxis (PrEP). We evaluated the performance of a qualitative assay that detects 20 antiretroviral...
20.
Chen I, Zhang Y, Cummings V, Cloherty G, Connor M, Beauchamp G, et al.
AIDS Res Hum Retroviruses
. 2017 Apr;
33(7):745-748.
PMID: 28384058
Resistance to reverse transcriptase and protease inhibitors was frequently detected in HIV from black men who have sex with men (MSM) enrolled in the HIV prevention trials network (HPTN) 061...